| A review on the role of machine learning in enabling IoT based healthcare applications HK Bharadwaj, A Agarwal, V Chamola, NR Lakkaniga, V Hassija, ... IEEE Access 9, 38859-38890, 2021 | 142 | 2021 |
| AI-enabled remote monitoring of vital signs for COVID-19: methods, prospects and challenges H Rohmetra, N Raghunath, P Narang, V Chamola, M Guizani, ... Computing, 1-27, 2023 | 69 | 2023 |
| Insights into current tropomyosin receptor kinase (TRK) inhibitors: development and clinical application W Yan, NR Lakkaniga, F Carlomagno, M Santoro, NQ McDonald, F Lv, ... Journal of medicinal chemistry 62 (4), 1731-1760, 2018 | 60 | 2018 |
| Catalyst free, C-3 functionalization of imidazo [1, 2-a] pyridines to rapidly access new chemical space for drug discovery efforts N Gunaganti, A Kharbanda, NR Lakkaniga, L Zhang, R Cooper, H Li, ... Chemical communications 54 (92), 12954-12957, 2018 | 34 | 2018 |
| The exploration of chirality for improved druggability within the human kinome D Saha, A Kharbanda, W Yan, NR Lakkaniga, B Frett, HY Li Journal of medicinal chemistry 63 (2), 441-469, 2019 | 28 | 2019 |
| Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression NR Lakkaniga, L Zhang, B Belachew, N Gunaganti, B Frett, H Li European Journal of Medicinal Chemistry, 112589, 2020 | 25 | 2020 |
| Bioisosteric discovery of NPA101. 3, a second-generation RET/VEGFR2 inhibitor optimized for single-agent polypharmacology M Moccia, B Frett, L Zhang, NR Lakkaniga, DC Briggs, R Chauhan, ... Journal of Medicinal Chemistry 63 (9), 4506-4516, 2020 | 21 | 2020 |
| Pyrrolo [2, 3-d] pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation NR Lakkaniga, N Gunaganti, L Zhang, B Belachew, B Frett, YK Leung, ... European journal of medicinal chemistry 206, 112691, 2020 | 19 | 2020 |
| Targeting rearranged during transfection in cancer: A perspective on small-molecule inhibitors and their clinical development D Saha, KR Ryan, NR Lakkaniga, B Acharya, NG Garcia, EL Smith, ... Journal of medicinal chemistry 64 (16), 11747-11773, 2021 | 18 | 2021 |
| FCX‐146, a potent allosteric inhibitor of Akt kinase in cancer cells: lead optimization of the second‐generation arylidene indanone scaffold M Balasubramaniam, NR Lakkaniga, AA Dera, MA Fayi, M Abohashrh, ... Biotechnology and Applied Biochemistry 68 (1), 82-91, 2021 | 18 | 2021 |
| Structural characterization of the aurora kinase B “DFG-flip” using metadynamics NR Lakkaniga, M Balasubramaniam, S Zhang, B Frett, H Li The AAPS journal 22, 1-9, 2020 | 17 | 2020 |
| Use of Imidazo[1,2‐a]pyridine as a Carbonyl Surrogate in a Mannich‐Like, Catalyst Free, One‐Pot Reaction G Naresh, NR Lakkaniga, A Kharbanda, W Yan, B Frett, H Li European Journal of Organic Chemistry 2019 (4), 770-777, 2019 | 15 | 2019 |
| Rational design, synthesis and biological evaluation of pyrimidine-4, 6-diamine derivatives as type-II inhibitors of FLT3 selective against c-KIT JB Bharate, N McConnell, G Naresh, L Zhang, NR Lakkaniga, L Ding, ... Scientific reports 8 (1), 3722, 2018 | 14 | 2018 |
| Discovery of imidazo [1, 2-a] pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 … L Zhang, NR Lakkaniga, JB Bharate, N Mcconnell, X Wang, A Kharbanda, ... European journal of medicinal chemistry 225, 113776, 2021 | 12 | 2021 |
| FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms B Acharya, D Saha, D Armstrong, NR Lakkaniga, B Frett RSC Medicinal Chemistry 13 (7), 798-816, 2022 | 10 | 2022 |
| Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases M Moccia, D Yang, NR Lakkaniga, B Frett, N McConnell, L Zhang, ... Scientific Reports 11 (1), 16103, 2021 | 7 | 2021 |
| Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease SK Bowroju, NR Penthala, NR Lakkaniga, M Balasubramaniam, ... Bioorganic & medicinal chemistry 45, 116311, 2021 | 6 | 2021 |
| Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose L Zhang, M Moccia, DC Briggs, JB Bharate, NR Lakkaniga, P Knowles, ... Journal of medicinal chemistry 65 (2), 1536-1551, 2022 | 4 | 2022 |
| Pyrazoloadenine inhibitors of the RET lung cancer oncoprotein discovered by a fragment optimization approach D Saha, KR Ryan, NR Lakkaniga, EL Smith, B Frett ChemMedChem 16 (10), 1605-1608, 2021 | 3 | 2021 |
| Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy NR Lakkaniga, Z Wang, Y Xiao, A Kharbanda, L Lan, H Li Medicinal Research Reviews 44 (2), 686-706, 2024 | 1 | 2024 |
